Results 161 to 170 of about 292,778 (314)

Metabolism‐Regulating Nanomedicines for Cancer Therapy

Advanced NanoBiomed Research, EarlyView.
This review highlights metabolism‐regulating nanomedicines designed to target glycolytic, lipid, amino acid, and nucleotide pathways in tumors. By incorporating metabolism‐regulating agents into versatile nanocarriers such as liposomes, micelles, dendrimers, and engineered bacteria, these platforms achieve targeted delivery, controlled release ...
Xiao Wu, Shiyi Geng, Jian Yang
wiley   +1 more source

Head and Neck Cancer Incidence in the United States Following the Onset of COVID-19 Pandemic. [PDF]

Laryngoscope Investig Otolaryngol
Cai WL, Helou V, Spector ME, Zevallos JP, Mazul AL, Contrera KJ.   +5 more
europepmc   +1 more source

Current conception of our hyperthermia therapy for head and neck cancer.

, 1989
Izumi Mataga, Morio Ozaki, Masanori Kondo, Yasukatsu HORIKAWA, Yasuyuki Narita, Nobuaki Higashino, Atsuo Okano, Kohzo Tsuchikawa, Joji Kato   +8 more
openalex   +2 more sources

Identification of a Proteolysis‐Targeting‐Chimera that Addresses Activated Checkpoint Kinase‐1 Reveals its Non‐Catalytic Functions in Tumor Cells

Angewandte Chemie International Edition, EarlyView.
In cancer cells, the induction of DNA replication stress by HU activates CHK1 by autophosphorylation. This leads to cell cycle arrest and recruits the DNA repair protein WRN to promote DNA repair and cell survival. In such cells, addition of the CHK1 inhibitor 9a propels DNA damage and apoptosis.
Ramy Ashry, Mohamed Abdelsalam, Julia Hausen, Christoph Hieber, Yanira Zeyn, Anne‐Christin Sarnow, Matthias Schmidt, Sara Najafi, Ina Oehme, Matthias Bros, Jia‐Xuan Chen, Mario Dejung, Wolfgang Sippl, Oliver H. Krämer   +13 more
wiley   +1 more source

Barriers and Timely Postoperative Radiation Therapy in Head and Neck Cancer. [PDF]

JAMA Otolaryngol Head Neck Surg
Nguyen MT, Kistner-Griffin E, DeMass R, Chera BS, Halbert CH, Sterba KR, Hill EG, Nussenbaum B, Alberg AJ, Sandulache VC, Hernandez DJ, Jackson RS, Puram SV, Kahmke R, Osazuwa-Peters N, Jackson G, Yom SS, Graboyes EM.   +17 more
europepmc   +1 more source

Twice a day versus once a day radiation therapy in head and neck cancer

, 1989
Niloy R. Datta, A.Dutta Choudhry, San Jay Gupta, A. Bose   +3 more
openalex   +1 more source

Sjögren Disease—B Cells at the Brink: From Autoimmunity to Lymphomagenesis and the Rise of Novel B Cell‐Targeted Therapies

Arthritis &Rheumatology, Accepted Article.
Sjögren disease (SjD) is a common systemic autoimmune disorder characterized by inflammation of the exocrine glands, resulting in dryness. Patients frequently exhibit extraglandular manifestations affecting various organ systems. To date, there are no FDA‐approved disease‐modifying therapies for SjD.
Rachael A. Gordon, Sara S. McCoy
wiley   +1 more source

Knowledge about head and neck cancer among adolescents. [PDF]

Braz J Otorhinolaryngol
Vasconcellos VM, Matos LL, Hojaij FC, Alves EM, Martins BCN, Nava AC.   +5 more
europepmc   +1 more source

Effects of Age and Nutritional Status on Surgical Outcomes in Head and Neck Cancer

, 1988
BERNARD S. LINN, David S. Robinson, Nancy G. Klimas   +2 more
openalex   +2 more sources

Low RYR2 Level Relates to Poor Prognosis of Patients With Lung Adenocarcinoma by Promoting Tumor Cell Proliferation and Inhibiting Immune Cell Infiltration

Biotechnology and Applied Biochemistry, EarlyView.
ABSTRACT Ryanodine receptor type 2 (RYR2) is a large calcium channel that has been identified as one of the most frequently mutated genes in lung adenocarcinoma (LUAD). Despite its potential significance, the role of RYR2 in LUAD remains poorly understood.
Tao Wang, Baozhen Wang, Zhongting Lu, Tao Li   +3 more
wiley   +1 more source